COVID‐19 pandemic and allergen immunotherapy—an EAACI survey

Autor: Isabel J. Skypala, Ludger Klimek, Montserrat Alvaro-Lozano, Oliver Pfaar, Ioana Agache, Helen A. Brough, Oscar Palomares, Adam Chaker, Eva Untersmayr, Jürgen Schwarze, Karin Hoffmann-Sommergruber, Erika Jensen-Jarolim, Mattia Giovannini, Marek Jutel, Charlotte G. Mortz, Cristina Quecchia, Aslı Gelincik, Antti Lauerma, Jolanta Walusiak-Skorupa, Vesna Tomic Spiric, Umit Murat Sahiner, María José Torres, Mónica Sandoval-Ruballos, Edward F. Knol, Tomas Chivato, Matteo Bonini, Liam O'Mahony, Radosław Gawlik, Carmen Riggioni, Stefano Del Giacco, Markus Ollert, Enrico Heffler
Přispěvatelé: HUS Inflammation Center, Department of Dermatology, Allergology and Venereology
Rok vydání: 2020
Předmět:
Intoxicative inhalant
Pediatrics
Allergy
IMPACT
SARS‐CoV‐2
0302 clinical medicine
Surveys and Questionnaires
Pandemic
Original Article: Allergen‐specific Immunotherapy and Biologics
Immunology and Allergy
0303 health sciences
allergen immunotherapy (AIT)
SARS-CoV-2
3. Good health
ddc
Tolerability
pandemic
COVID-19
safety
Allergen immunotherapy
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Immunology
03 medical and health sciences
Original Articles: Allergen‐specific Immunotherapy and Biologics
COVID‐19
medicine
Humans
survey
TELEMEDICINE
practicability
Pandemics
030304 developmental biology
Asthma
Retrospective Studies
business.industry
SERVICES
medicine.disease
RHINOCONJUNCTIVITIS
030228 respiratory system
Desensitization
Immunologic
3121 General medicine
internal medicine and other clinical medicine
ASTHMA
business
Zdroj: Pfaar, O, Agache, I, Bonini, M, Brough, H A, Chivato, T, Del Giacco, S R, Gawlik, R, Gelincik, A, Hoffmann-sommergruber, K, Jutel, M, Klimek, L, Knol, E F, Lauerma, A, Ollert, M, O’mahony, L, Mortz, C G, Palomares, O, Riggioni, C, Schwarze, J, Skypala, I, Torres, M J, Untersmayr, E, Walusiak-skorupa, J, Chaker, A, Giovannini, M, Heffler, E, Jensen-jarolim, E, Quecchia, C, Sandoval-ruballos, M, Sahiner, U, Tomić Spirić, V & Alvaro-lozano, M 2021, ' COVID-19 pandemic and allergen immunotherapy – an EAACI survey ', Allergy, vol. 76, no. 11, pp. 3504-3516 . https://doi.org/10.1111/all.14793
ALLERGY
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
Pfaar, O, Agache, I, Bonini, M, Brough, H A, Chivato, T, Del Giacco, S R, Gawlik, R, Gelincik, A, Hoffmann-Sommergruber, K, Jutel, M, Klimek, L, Knol, E F, Lauerma, A, Ollert, M, O’Mahony, L, Mortz, C G, Palomares, O, Riggioni, C, Schwarze, J, Skypala, I, Torres, M J, Untersmayr, E, Walusiak-Skorupa, J, Chaker, A, Giovannini, M, Heffler, E, Jensen-Jarolim, E, Quecchia, C, Sandoval-Ruballos, M, Sahiner, U, Tomić Spirić, V & Alvaro-Lozano, M 2021, ' COVID-19 pandemic and allergen immunotherapy—an EAACI survey ', Allergy: European Journal of Allergy and Clinical Immunology, vol. 76, no. 11, pp. 3504-3516 . https://doi.org/10.1111/all.14793
Allergy
ISSN: 0105-4538
DOI: 10.1111/all.14793
Popis: Background: As in many fields of medical care, the coronavirus disease 2019 (COVID-19) resulted in an increased uncertainty regarding the safety of allergen immunotherapy (AIT). Therefore, the European Academy of Allergy and Clinical Immunology (EAACI) aimed to analyze the situation in different countries and systematically collect all information available regarding tolerability and possible amendments in daily practice of sublingual AIT (SLIT), subcutaneous AIT (SCIT) for inhalant allergies and venom AIT.Method: Under the framework of the EAACI, a panel of experts in the field of AIT coordinated by the Immunotherapy Interest Group (IT IG) set-up a web-based retrospective survey (SurveyMonkey®) including 27 standardized questions on practical and safety aspects on AIT in worldwide clinical routine. Results: 417 respondents providing AIT to their patients in daily routine answered the survey. For patients (without any current symptoms to suspect COVID-19), 60% of the respondents informed of not having initiated SCIT (40% venom AIT, 35% SLIT) whereas for the maintenance phase of AIT, SCIT was performed by 75% of the respondents (74% venom AIT, 89% SLIT). No tolerability concern arises from this preliminary analysis. 16 physicians reported having performed AIT despite (early) symptoms of COVID-19 and/or a positive test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Conclusions: This first international retrospective survey in atopic diseases investigated practical aspects and tolerability of AIT during the COVID-19 pandemic and gave no concerns regarding reduced tolerability under real-life circumstances. However, the data indicate an undertreatment of AIT, which may be temporary, but could have a long-lasting negative impact on the clinical care of allergic patients. Keywords: COVID-19, allergen immunotherapy (AIT), SARS-CoV-2, practicability, survey, safety, pandemic
Databáze: OpenAIRE
Externí odkaz: